![James M. Hinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James M. Hinson
Corporate Officer/Principal chez Unicorn Pharma Consulting, Inc.
Postes actifs de James M. Hinson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Unicorn Pharma Consulting, Inc. | Corporate Officer/Principal | 06/11/2009 | - |
Historique de carrière de James M. Hinson
Anciens postes connus de James M. Hinson
Sociétés | Poste | Début | Fin |
---|---|---|---|
Aldagen, Inc.
![]() Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Directeur Technique/Scientifique/R&D | 06/11/2009 | - |
Corporate Officer/Principal | 06/11/2009 | 06/11/2009 |
Formation de James M. Hinson
Vanderbilt University | Doctorate Degree |
University of Missouri | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Aldagen, Inc.
![]() Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
Unicorn Pharma Consulting, Inc. |
- Bourse
- Insiders
- James M. Hinson
- Expérience